GO:0032500 muramyl dipeptide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032500 muramyl dipeptide binding describes the selective, non-covalent interaction of a protein with muramyl dipeptide (MDP), a peptidoglycan-derived fragment.
• The best-characterized MDP-binding protein is NOD2, which directly binds MDP and ATP to initiate innate immune signaling.
• MDP binding to NOD2 is enhanced by membrane targeting and interaction with Arf6-GTPase in mammalian cells.
• NOD2 activation by MDP protects against experimental colitis and negatively regulates TLR9-mediated colonic inflammation.
• MDP-based analogs are being explored as anticancer compounds and artificial nanobacteria for systemic antitumor immunity.
• Studying GO:0032500 requires methods such as CRISPR knockout, point mutation, knock-in, and biochemical binding assays.
Description
Muramyl dipeptide (MDP) is the minimal bioactive fragment of bacterial peptidoglycan, and its recognition by host proteins is a cornerstone of innate immune sensing. The Gene Ontology term GO:0032500, muramyl dipeptide binding, defines the selective, non-covalent interaction between a protein and MDP. This molecular function is critical for detecting bacterial components and initiating downstream signaling cascades that shape inflammation and antimicrobial defense. Researchers study MDP binding to understand how the immune system distinguishes commensal from pathogenic bacteria and to develop therapeutics for inflammatory diseases and cancer. The most extensively studied MDP-binding protein is NOD2, a cytosolic pattern recognition receptor that directly binds MDP and ATP. Membrane targeting and interaction with Arf6-GTPase enhance MDP binding to NOD2 in mammalian cells, highlighting the importance of subcellular localization for this function. MDP binding to NOD2 triggers signaling that can both protect against colitis and negatively regulate TLR9-mediated inflammation through deubiquitinating enzyme A. Beyond NOD2, other NLR proteins such as NLRP1 may sense MDP-related ligands, though direct binding evidence is still emerging. The therapeutic potential of MDP binding is underscored by the development of MDP-based analogs as anticancer compounds and MDP-presenting polymersomes that boost antitumor immunity. Understanding the molecular details of GO:0032500 is therefore essential for immunology, microbiology, and drug discovery.
muramyl dipeptide binding At A Glance
| GO ID | GO:0032500 |
|---|---|
| GO term | muramyl dipeptide binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Non-covalent recognition of muramyl dipeptide (MDP) by host proteins, initiating innate immune signaling |
| Key protein | NOD2 (nucleotide-binding oligomerization domain-containing protein 2) |
| Subcellular context | Cytosol and membrane-associated compartments; membrane targeting enhances MDP binding to NOD2 |
| Regulatory cofactor | ATP binding to NOD2 is required for MDP-induced signaling |
| Disease relevance | Inflammatory bowel disease, colitis, and cancer immunotherapy |
What Is GO:0032500?
GO:0032500 muramyl dipeptide binding is a molecular function defined as interacting selectively and non-covalently with muramyl dipeptide, a molecule derived from peptidoglycan. This binding event is a key step in bacterial sensing by host pattern recognition receptors, particularly NOD2, and does not involve covalent modification of the ligand.
Why Is muramyl dipeptide binding Important in Cell Biology?
GO:0032500 muramyl dipeptide binding is important because it represents the first molecular recognition step in a major innate immune sensing pathway that controls inflammation, bacterial clearance, and tissue homeostasis. Dysregulation of MDP binding and downstream NOD2 signaling is linked to inflammatory bowel diseases, and MDP-based compounds are being developed as vaccine adjuvants and anticancer agents.
• MDP binding by NOD2 is essential for sensing bacterial peptidoglycan and mounting an immune response.
• NOD2 activation by MDP protects mice from experimental colitis, highlighting a role in intestinal homeostasis.
• MDP binding negatively regulates TLR9-mediated colonic inflammation through induction of deubiquitinating enzyme A.
• MDP-based analogs show potential as anticancer compounds with improved selectivity and biocompatibility.
• MDP-presenting polymersomes act as artificial nanobacteria to boost systemic antitumor immunity.
• Membrane targeting and Arf6-GTPase enhance MDP binding to NOD2, linking membrane trafficking to innate immunity.
• NOD2 is a major susceptibility gene for Crohn's disease, and MDP binding is central to its function.
• Other NLR proteins such as NLRP1 may sense MDP-related ligands, expanding the scope of MDP binding in inflammasome biology.
• Understanding MDP binding aids in designing therapeutics that modulate innate immune responses.
• GO:0032500 provides a defined molecular function for annotating genes involved in bacterial recognition.
Molecular Mechanism of muramyl dipeptide binding
Direct Binding of MDP to NOD2
In simple terms: MDP physically attaches to the NOD2 protein like a key in a lock.
NOD2 directly binds muramyl dipeptide (MDP) and ATP, as demonstrated by biochemical and structural studies. This direct interaction is required for NOD2 activation and downstream signaling. The binding is non-covalent and selective for MDP, distinguishing it from other peptidoglycan fragments.
Role of ATP in MDP Binding and Signaling
In simple terms: ATP acts as a co-factor that helps NOD2 function after MDP binds.
NOD2 binding to MDP is coupled with ATP binding, which is necessary for NOD2 oligomerization and signal transduction. ATP is not covalently modified but is required for the conformational changes that activate NOD2. This dual-ligand requirement ensures that signaling only occurs when both bacterial MDP and cellular ATP are present.
Membrane Targeting and Arf6-GTPase Enhancement
In simple terms: Membrane localization and a small GTPase called Arf6 help NOD2 bind MDP more efficiently.
Membrane targeting enhances MDP binding to NOD2 and Arf6-GTPase in mammalian cells. Arf6-GTPase is involved in membrane trafficking, and its interaction with NOD2 at membranes promotes efficient MDP recognition. This suggests that subcellular localization is a key determinant of GO:0032500 activity.
Downstream Signaling and Regulation by Deubiquitinating Enzyme A
In simple terms: After MDP binds, NOD2 triggers signals that can dampen other inflammatory pathways.
MDP activation of NOD2 negatively regulates TLR9-mediated colonic inflammation through the induction of deubiquitinating enzyme A expression. This cross-talk between NOD2 and TLR9 pathways highlights the regulatory complexity of MDP binding. The induction of deubiquitinating enzyme A represents a mechanism by which MDP binding shapes the inflammatory response.
MDP-Based Analogs and Artificial Nanobacteria
In simple terms: Synthetic versions of MDP can be used to trigger immune responses for therapy.
MDP-based analogs have been developed as potential anticancer compounds with improved selectivity and biocompatibility. Additionally, MDP-presenting polymersomes act as artificial nanobacteria to boost systemic antitumor immunity. These applications exploit the natural MDP binding function to activate immune cells in a controlled manner.
Key Genes Involved in GO:0032500 muramyl dipeptide binding
The following genes and proteins are directly involved in or closely associated with muramyl dipeptide binding (GO:0032500) and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NOD2 | Directly binds MDP and ATP to initiate innate immune signaling | Central to MDP binding studies; mutations linked to Crohn's disease |
| ARF6 | GTPase that enhances MDP binding to NOD2 at membranes | Modulates membrane trafficking and MDP recognition efficiency |
| NLRP1 | Inflammasome sensor that may respond to MDP-related ligands | Potential alternative MDP-binding protein in inflammasome pathways |
| TLR9 | Toll-like receptor whose signaling is negatively regulated by MDP-activated NOD2 | Cross-talk target for understanding MDP-mediated immune regulation |
| DUBA (OTUD5) | Deubiquitinating enzyme A induced by MDP-NOD2 signaling | Mediates negative regulation of TLR9 inflammation |
| RIP2 (RIPK2) | Kinase downstream of NOD2 activation | Signaling mediator after MDP binding |
| TAK1 (MAP3K7) | Kinase in NOD2 signaling pathway | Downstream effector of MDP-induced NF-kB activation |
| IKK complex | Activates NF-kB after NOD2 stimulation | Transcription factor activation downstream of MDP binding |
| NF-kB | Transcription factor driving inflammatory gene expression | Readout of MDP-NOD2 pathway activation |
| CARD9 | Adaptor protein in NOD2 signaling | Links MDP sensing to antifungal and antibacterial immunity |
| ATG16L1 | Autophagy-related protein linked to NOD2 function | Crohn's disease susceptibility gene interacting with MDP pathway |
| IRGM | Autophagy regulator associated with NOD2 | Modulates MDP-induced autophagy and inflammation |
| XBP1 | Transcription factor in ER stress response linked to NOD2 | May influence MDP-induced cytokine production |
| IL-10 | Anti-inflammatory cytokine induced by MDP-NOD2 signaling | Protective role in colitis models |
| IL-6 | Pro-inflammatory cytokine modulated by MDP | Marker of MDP-induced inflammation |
| TNF-alpha | Pro-inflammatory cytokine induced by MDP | Readout of NOD2 activation |
| MDP itself | Ligand for GO:0032500 | Used in binding assays and therapeutic analogs |
How Is muramyl dipeptide binding Regulated?
MDP binding to NOD2 is regulated by ATP binding, which is required for NOD2 activation and signaling. Membrane targeting and interaction with Arf6-GTPase enhance MDP binding efficiency in mammalian cells. Downstream, MDP-activated NOD2 induces deubiquitinating enzyme A, which negatively regulates TLR9-mediated inflammation, providing a feedback mechanism. Additionally, MDP-based analogs and polymersomes can modulate the immune response by engaging MDP-binding proteins.
muramyl dipeptide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NOD2 | Crohn's disease, colitis, impaired bacterial sensing | Nod2 knockout mice, MDP-induced colitis models |
| ARF6 | Membrane trafficking and MDP binding efficiency | Arf6 knockdown or knockout cells, membrane-targeting assays |
| NLRP1 | Inflammasome-related autoinflammatory disorders | Nlrp1 knockout macrophages, MDP stimulation |
| TLR9 | Colonic inflammation and cross-talk with NOD2 | Tlr9 knockout mice, MDP treatment |
| DUBA (OTUD5) | Negative regulation of TLR9 inflammation | OTUD5 knockout or overexpression in colonic cells |
Inflammatory Bowel Disease and Colitis
MDP activation of NOD2 protects mice from experimental colitis, indicating a protective role for MDP binding in intestinal inflammation. NOD2 is a major susceptibility gene for Crohn's disease, and impaired MDP sensing contributes to disease pathogenesis. MDP binding negatively regulates TLR9-mediated colonic inflammation through induction of deubiquitinating enzyme A, highlighting a regulatory axis that could be targeted therapeutically.
Cancer Immunotherapy
MDP-based analogs are being developed as potential anticancer compounds with improved selectivity and biocompatibility. MDP-presenting polymersomes act as artificial nanobacteria to boost systemic antitumor immunity, demonstrating that MDP binding can be harnessed for cancer therapy. These strategies exploit the innate immune sensing of MDP to activate antitumor responses.
Inflammasome-Related Disorders
NLRP1 inflammasomes may sense MDP-related ligands, linking MDP binding to inflammasome activation and pyroptosis. Dysregulated inflammasome activity is associated with autoinflammatory and autoimmune conditions, suggesting that MDP binding proteins beyond NOD2 could contribute to disease.
From muramyl dipeptide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NOD2 directly bind MDP? | Recombinant NOD2 protein, isothermal titration calorimetry, or surface plasmon resonance |
| How does membrane targeting affect MDP binding? | Membrane-targeted NOD2 constructs in mammalian cells |
| What is the role of Arf6 in MDP binding? | ARF6 knockout or knockdown cells with MDP stimulation |
| Does MDP protect against colitis? | Nod2 knockout mice in experimental colitis models |
| Can MDP analogs boost antitumor immunity? | MDP-presenting polymersomes in mouse tumor models |
| How does MDP regulate TLR9 signaling? | TLR9-expressing cells treated with MDP and DUBA knockdown |
How to Study the muramyl dipeptide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry | Binding affinity and stoichiometry of MDP to NOD2 | Direct MDP binding studies |
| Surface plasmon resonance | Real-time binding kinetics | MDP-NOD2 interaction analysis |
| Luciferase reporter assay | NF-kB activation after MDP stimulation | Functional readout of MDP binding |
| ELISA | Cytokine production (IL-6, TNF-alpha) | MDP-induced inflammation |
| CRISPR knockout | Loss of gene function | Testing requirement of NOD2 or ARF6 for MDP binding |
| Membrane fractionation | Subcellular localization of NOD2 | Assessing membrane targeting effect on MDP binding |
| Mouse colitis model | Intestinal inflammation severity | Evaluating protective role of MDP-NOD2 signaling |
| Tumor immunotherapy model | Antitumor immune response | Testing MDP-presenting polymersomes |
Biochemical Binding Assays
Direct binding of MDP to NOD2 can be measured using isothermal titration calorimetry, surface plasmon resonance, or radioligand binding assays. These methods provide quantitative affinity data and confirm non-covalent interaction. Membrane targeting can be assessed by adding liposomes or membrane fractions to binding reactions.
Cell-Based Signaling Assays
MDP-induced NF-kB activation and cytokine production are commonly measured using luciferase reporter assays and ELISA in macrophage or epithelial cell lines. Knockout of NOD2 or ARF6 abolishes or reduces these responses, confirming specificity. Cross-talk with TLR9 can be studied by co-stimulation with MDP and CpG DNA.
CRISPR-Based Genetic Models
CRISPR knockout of NOD2, ARF6, or OTUD5 in cell lines or mice enables loss-of-function studies of MDP binding. Point mutations in the NOD2 ligand-binding domain can dissect residues critical for MDP recognition. Knock-in of tagged NOD2 allows localization and interaction studies.
In Vivo Colitis and Tumor Models
Experimental colitis models in mice, such as DSS-induced colitis, are used to test the protective role of MDP-NOD2 signaling. Tumor models treated with MDP-presenting polymersomes assess antitumor immunity. These in vivo systems link MDP binding to organism-level outcomes.
How CRISPR Can Be Used to Study GO:0032500 muramyl dipeptide binding
Knockout
CRISPR knockout of NOD2, ARF6, or OTUD5 is used to abolish MDP binding and downstream signaling, confirming the requirement of these genes. Nod2 knockout mice are a standard model for studying MDP protection in colitis. Knockout of ARF6 reduces MDP binding efficiency in mammalian cells.
Point Mutation
Point mutations in the NOD2 ligand-binding domain can identify residues critical for MDP recognition. Such mutations may mimic Crohn's disease-associated variants and help dissect loss-of-function mechanisms. CRISPR-mediated point mutation allows precise editing without altering other regions.
Knock-in
Knock-in of epitope-tagged NOD2 or ARF6 enables localization and interaction studies in cells. Tagged knock-in models can be used to track MDP-induced trafficking and complex formation. Knock-in of disease-associated NOD2 variants helps evaluate their impact on MDP binding.
Overexpression
Overexpression of NOD2 or ARF6 enhances MDP binding and signaling in cell-based assays. Overexpression of DUBA (OTUD5) can suppress TLR9-mediated inflammation, mimicking MDP-induced negative regulation. Overexpression systems are useful for biochemical purification of MDP-binding complexes.
How EDITGENE Supports muramyl dipeptide binding Research
Researchers studying muramyl dipeptide binding-related genes often need to determine whether a candidate gene is causally involved in MDP recognition, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR services to create precisely engineered cell and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for muramyl dipeptide binding research.
Frequently Asked Questions About muramyl dipeptide binding
What is muramyl dipeptide binding?
Muramyl dipeptide binding (GO:0032500) is the selective, non-covalent interaction of a protein with muramyl dipeptide, a peptidoglycan-derived molecule, as defined by the Gene Ontology.
What genes are involved in muramyl dipeptide binding?
The best-characterized gene is NOD2, which directly binds MDP and ATP. ARF6 enhances MDP binding to NOD2 at membranes, and other genes such as NLRP1 and OTUD5 are also implicated.
How does NOD2 bind muramyl dipeptide?
NOD2 directly binds MDP in a non-covalent manner, and this interaction is coupled with ATP binding to initiate signaling. Membrane targeting and Arf6-GTPase further enhance this binding.
What diseases are associated with muramyl dipeptide binding?
MDP binding is linked to inflammatory bowel disease, colitis, and cancer immunotherapy. NOD2 mutations are a major risk factor for Crohn's disease.
How can I study muramyl dipeptide binding in the lab?
Common methods include isothermal titration calorimetry, surface plasmon resonance, luciferase reporter assays, ELISA, and CRISPR knockout models.
What is the role of ATP in muramyl dipeptide binding?
ATP binding to NOD2 is required for MDP-induced signaling and is thought to promote conformational changes necessary for activation.
Does membrane targeting affect muramyl dipeptide binding?
Yes, membrane targeting enhances MDP binding to NOD2 and Arf6-GTPase in mammalian cells.
Can muramyl dipeptide be used in cancer therapy?
MDP-based analogs and MDP-presenting polymersomes are being developed as anticancer compounds and artificial nanobacteria to boost antitumor immunity.
What is the GO ID for muramyl dipeptide binding?
The GO ID is GO:0032500, under the molecular_function ontology.
How does MDP binding regulate inflammation?
MDP-activated NOD2 can negatively regulate TLR9-mediated colonic inflammation through induction of deubiquitinating enzyme A, and it protects against experimental colitis.
Conclusion
GO:0032500 muramyl dipeptide binding is a fundamental molecular function in innate immunity, primarily mediated by NOD2 and modulated by ARF6 and ATP. Its dysregulation is linked to inflammatory bowel diseases and its therapeutic potential is being explored in cancer immunotherapy. Continued research using CRISPR models and biochemical assays will further illuminate the mechanisms and translational opportunities of MDP binding.
References
- 1. Hespen CW et al.. 2022. Membrane targeting enhances muramyl dipeptide binding to NOD2 and Arf6-GTPase in mammalian cells.. Chem Commun (Camb) 58(46):6598-6601 PMID: 35584401
- 2. Masuta Y et al.. 2023. Activation of nucleotide-binding oligomerization domain 2 by muramyl dipeptide negatively regulates Toll-like receptor 9-mediated colonic inflammation through the induction of deubiquitinating enzyme A expression.. Int Immunol 35(2):79-94 PMID: 36171063
- 3. Chavarría-Smith J et al.. 2015. The NLRP1 inflammasomes.. Immunol Rev 265(1):22-34 PMID: 25879281
- 4. Iwicka E et al.. 2022. Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency.. Front Oncol 12:970967 PMID: 36237313
- 5. Watanabe T et al.. 2008. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.. J Clin Invest 118(2):545-59 PMID: 18188453
- 6. Mo J et al.. 2012. Pathogen sensing by nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide and ATP.. J Biol Chem 287(27):23057-67 PMID: 22549783
- 7. Al Nabhani Z et al.. 2017. Nod2: The intestinal gate keeper.. PLoS Pathog 13(3):e1006177 PMID: 28253332
- 8. Cui G et al.. 2024. Muramyl Dipeptide-Presenting Polymersomes as Artificial Nanobacteria to Boost Systemic Antitumor Immunity.. ACS Appl Mater Interfaces 16(45):61655-61663 PMID: 39498882
